Safety and Immunogenicity Study of Influenza Vaccines in HIV-infected and HIV-uninfected Pregnant Women in Western Kenya
|ClinicalTrials.gov Identifier: NCT01810731|
Recruitment Status : Withdrawn (Scientific review positive from 3 manufacturers; internal committees did not support due to deploying new flu vaccines in HIV+ pregnant women in Kenya.)
First Posted : March 13, 2013
Last Update Posted : April 10, 2014
|Condition or disease||Intervention/treatment||Phase|
|Influenza, Human HIV Malaria Tetanus Polio||Biological: Quadrivalent Inactivated Influenza Vaccine (QIV) Biological: Inactivated Polio Vaccine Biological: Double Dose QIV||Phase 2 Phase 3|
Hide Detailed Description
Recent investments in influenza surveillance in many African countries confirm results from other countries that young children, pregnant women, and those with chronic medical conditions are at increased risk of hospitalization and death from influenza infection. Annual influenza vaccination is the most effective method for preventing influenza virus infection and its complications. Vaccination is currently recommended in high risk groups in many developed countries and the WHO Strategic Advisory Group of Experts (SAGE) on Immunization made a recommendation for vaccination of pregnant women in their 2005 position paper on influenza vaccine. In 2012, the SAGE further concluded that pregnant women are the most important risk group for inactivated seasonal influenza vaccination based upon "compelling evidence of substantial risk of severe disease in this group and evidence that seasonal influenza vaccine is safe and effective in preventing disease in pregnant women as well as their young infants, in whom disease burden is also high".
Maternal influenza immunization is viewed as the most effective way to protect infants less than 6 months of age who are not yet eligible for immunization. In the United States, children under 6 months experience very high rates of influenza-associated hospitalization and are among those most at risk of severe outcomes. Recent data from Kenya, similarly suggest rates of influenza-associated hospitalizations in children under age 1 to be as high, or higher, than those observed in the United States. Vaccination of pregnant women provides protection to their infants against laboratory-confirmed influenza illness in the first months of life. Furthermore, vaccination of pregnant women has been associated with a decreased risk of pre-term birth and small for gestational age in Canada and the state of Georgia in the US, and increased birth weight in infants during periods of high transmission in Bangladesh. However, traditional TIV may have reduced immunogenicity in HIV-infected adults, and HIV infection has been shown to reduce placental transfer of both tetanus and measles antibodies. The high prevalence of other diseases, including malaria and malnutrition, may also impact the effectiveness of influenza vaccination for pregnant women and their infants in sub-Saharan Africa.
Use of double dose QIV may produce a greater immune response in pregnant women and increased antibody production may improve transplacental transfer of influenza antibodies to the developing fetus, conferring a better or possibly longer duration of protection from influenza infection. Therefore, we propose to conduct a randomized controlled trial of influenza vaccines in a high HIV-prevalence, malaria-endemic setting in Kenya, using inactivated polio vaccine (IPV) as a comparator/control. We propose to assess the safety, immunogenicity, and efficacy of standard dose (15 µg) QIV (FLUARIX® (GlaxoSmithKline Biologicals, Dresden, Germany) and double dose (30 µg) QIV in HIV-infected and HIV-uninfected pregnant women.
- To evaluate the immunogenicity of standard dose (15 µg) QIV and double dose (30 µg) QIV in HIV-infected and uninfected pregnant women
- To evaluate the level of vaccine-induced influenza antibody transfer to infants of HIV-infected and uninfected pregnant women who receive standard dose (15 µg) QIV or double dose (30 µg) QIV
- To evaluate the safety of standard dose (15 µg) QIV and double dose (30 µg) QIV in HIV-infected and HIV-uninfected pregnant women and fetus
This trial will be conducted as a double-blind, randomized, controlled trial stratified by HIV status in up to 720 pregnant women in their second and third trimesters and their infants residing in health and demographic surveillance sites (HDSS) around Siaya District Hospital and Lwak Mission Hospital in Nyanza Province, Western Kenya. The study will be conducted in accordance with International Conference on Harmonization Good Clinical Practice (GCP) standards. Mothers must agree to be counseled and tested for HIV at the time of screening and enrollment unless there is written documentation of HIV infection or a negative HIV test in the last 3 months. After initial screening for eligibility and informed consent, enrolled women will be stratified by HIV status (infected, uninfected) and block randomized in a 1:1:1:1 ratio to receive standard dose (15 µg) QIV, double dose (30 µg) QIV or IPV. The day of vaccination will be considered study Day 0 for each subject. Each subject will receive a single vaccination. For the first 240 enrolled women, study personnel will visit their homes on Days 1, 2, and 3 to do active surveillance for adverse events following vaccination. Pregnancy outcomes will be recorded for all subjects (live birth, still birth, or spontaneous abortion). HIV testing will be repeated at birth for all women with negative results at screening. Live and still born infants will be examined by trained study personnel in the first 24 hours after delivery to determine birth weight, length, assess gestational age, and identify possible congenital anomalies associated with vaccination.
All enrolled subjects will be asked to return to the antenatal study clinic on Study Day 7, Day 28, Day 56 (if not delivered), for delivery, and for any febrile or respiratory illness or other concern. During the enrollment process, their mobile telephone number will be recorded (or a number will be recorded for someone they identify in the village with a mobile telephone who will be willing to transmit information to them). Participants will be contacted by phone or in person every 2 weeks to determine if they have had fever and/or cough during the prior 2 weeks. Subjects with fever only will receive a malaria smear and other treatment as appropriate per Kenya Ministry of Health (MOH) guidelines. Subjects with fever or cough will have respiratory specimens collected via placement of NP/OP swabs by trained clinical personnel for influenza testing. After delivery, subjects will be asked to bring infants to the study clinic for evaluation on Days 7, 42, and 70 of life and when the child is approximately 6 months of age. Infants will also be under surveillance for fever, history of fever, hypothermia and/or cough for the first 6 months of life. All febrile, hypothermic, and/or coughing infants will receive testing for malaria and nasopharyngeal (NP)and oropharyngeal (OP) swabs for influenza. Febrile infants under 2 months of age will receive additional testing and treatment per national guidelines. Any infant admitted to the hospital with any respiratory symptom, hypothermia, apnea or fever will receive testing for influenza by real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) of NP/OP specimens.
Vaccine immunogenicity will be evaluated by comparing hemagglutination inhibition (HI) titers on Day 0 and Day 28 and at delivery in the mother, in cord blood, in the mother and infant at infant Day 70 of life, and in the infant at approximately 6 months of age. We will determine the proportion of vaccinated women who achieve a fourfold rise in HI titers post-vaccination compared to pre-vaccination or an HI titer ≥40 for subjects with baseline HI titer <10, compared to the same outcome in controls. The proportion of HI titers ≥40 in cord blood and in infants will also be measured and compared among vaccine recipients and controls. Geometric means of HI titers will also be compared.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Double-Blind, Randomized, Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Standard Dose Quadrivalent Inactivated Influenza Vaccine, and Double Dose Quadrivalent Inactivated Influenza Vaccine in HIV-Infected and HIV-Uninfected Pregnant Women in a Malaria-Endemic Area of Rural Western Kenya|
|Study Start Date :||April 2014|
|Primary Completion Date :||April 2014|
|Study Completion Date :||April 2014|
Experimental: Quadrivalent Influenza Vaccine (QIV)
15µg of each of 2 influenza A strains (H1N1 and H3N2) and 2 influenza B strains in a buffer solution totaling 0.5mL which is administered intramuscularly.
Administered as a single dose on the day of enrollment.
Biological: Quadrivalent Inactivated Influenza Vaccine (QIV)
Other Name: Fluarix, (GlaxoSmithKline Biologicals, Dresden, Germany)
Active Comparator: Inactivated Polio Vaccine
A sterile suspension of three types of poliovirus: Type 1 (Mahoney), Type 2 (MEF1) and Type 3 (Saukett). This vaccine is prepared from types 1, 2 and 3 of poliomyelitis virus cultured on Vero cells, purified and then inactivated by formaldehyde and administered as a 0.5ml intramuscular or subcutaneous injection. A single dose of vaccine will be administered upon enrollment.
Biological: Inactivated Polio Vaccine
Other Name: Imovax, Sanofi Pasteur SA
Experimental: Double Dose QIV
30µg of each of 2 influenza A strains (H1N1 and H3N2) and 2 influenza B strains in a buffer solution totaling 1.0mL which is administered intramuscularly.
Administered as a single dose on the day of enrollment.
Biological: Double Dose QIV
Other Name: Fluarix (GlaxoSmithKline Biologicals, Dresden, Germany)
- Proportion of women with an appropriate rise in Hemagglutination Inhibition (HI) titers [ Time Frame: Enrollment (Day 0) vs. Day 28 for each study arm ]The proportion of standard dose (15 µg) QIV and double dose (30 µg) QIV recipients with a fourfold rise in HI titers or HI titers ≥40 if baseline HI titer <10 compared to the same proportion in controls
- Proportion of infants born to standard dose (15 µg) QIV and double dose (30 µg) QIV recipients with HI titers greater than or equal to 40 in cord blood compared to same in controls. [ Time Frame: At delivery ]
- Number of solicited and unsolicited adverse events post-vaccination by study arm [ Time Frame: During follow-up period, approx. 9 months ]
- Vaccine efficacy of standard dose (15 µg) QIV and double dose (30 µg) QIV in mothers and infants compared to control mothers and infants. [ Time Frame: Entire follow-up period, approx. 9 months ]Incidence of influenza infection will be measured in all participants by surveillance for influenza-like illness (ILI) throughout the study period. Women with fever and cough will be tested for influenza via rRT-PCR of NP/OP swabs. Infants with fever, hypothermia, apnea or any respiratory symptom will also be tested for influenza via rRT-PCR of NP/OP swabs.
- HIV infection and placental antibody transfer [ Time Frame: Delivery ]Compare geometric mean HI titers and geometric mean tetanus antibody titers at delivery in HIV-infected and HIV-uninfected mothers with titers in cord blood.
- Birth weight [ Time Frame: Delivery ]Compare birth weight adjusted for gestational age among standard dose (15 µg) QIV and double dose (30 µg) QIV recipients compared to controls.
- Peripheral and placental parasitemia impact on vaccination [ Time Frame: Day 0 and delivery ]Compare change in geometric mean HI titers from day 0 to day 28 in women with and without peripheral parasitemia at the time of vaccination. Compare amount of passive antibody transfer to infants in cord blood in mothers with and without placental parasitemia
- baseline polio immunity and polio antibody transfer [ Time Frame: day 0 and delivery ]Assess baseline immunity to polio types 1, 2, 3 among all study participants. Assess polio antibody transfer to infants from mothers who did and did not receive IPV.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01810731
|Siaya District Hospital|
|Study Director:||Meredith L McMorrow, MD, MPH||Centers for Disease Control and Prevention|
|Principal Investigator:||Joshua A Mott, PhD||Centers for Disease Control and Prevention Kenya Country Office|
|Principal Investigator:||Nancy Otieno, MS||Kenya Medical Research Institute|
|Study Director:||Marc-Alain Widdowson, VetMB, MSc||Centers for Disease Control and Prevention|